A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)?

  • Markowitz, Avi, (PI)

    Project: Other project

    StatusFinished
    Effective start/end date7/30/1312/31/16

    Funding

    • Bayer HealthCare Pharmaceuticals: $16,574.00